Total peripheral resistance responsiveness during the development of secondary renal hypertension in dogs.
OBJECTIVE
To determine whether the responses of total peripheral resistance and arterial pressure to vasoconstrictor agents are amplified as renovascular hypertension develops in dogs.


METHODS
After baseline measurements, the effects of renal artery stenosis (1K, 1C hypertension) were studied in groups of untreated and enalapril-treated dogs early (1-3 weeks) and later (4-6 weeks) as the hypertension developed. Both resting and open-loop haemodynamic measurements were made and the effects of acute intravenous infusions of vasopressin (0.25, 0.5 and 1.25 ng/kg per min) and phenylephrine (0.125, 0.25 and 0.50 microg/kg per min on arterial pressure, cardiac output and calculated total peripheral resistance responses were measured.


RESULTS
Renal artery stenosis induced an increase in arterial blood pressure in both groups of dogs, with similar changes in haemodynamics also observed in open-loop conditions. The slopes of arterial pressure and peripheral resistance responses to vasopressin and phenylephrine were not significantly changed in early or late hypertension, in either the untreated or enalapril-treated groups.


CONCLUSIONS
Hypertension from renal artery stenosis in dogs was due to nonautonomic, nonangiotensin II mechanisms. There was no evidence of vascular amplification of the effects of vasoconstrictor agents, indicating that this did not play a role in the development of hypertension.
Anderson
Warwick P
WP
Department of Physiology, School of Biomedical Sciences, Monash University, Melbourne, Victoria, Australia. warwick.anderson@nhmrc.gov.au
Shweta
Amany
A
Evans
Roger G
RG
Edgley
Amanda J
AJ
Gao
Yi
Y
D000806:Angiotensin-Converting Enzyme Inhibitors / Q000494:pharmacology*; D000818:Animals; D001127:Arginine Vasopressin / Q000494:pharmacology; D001794:Blood Pressure / Q000187:drug effects*; D002216:Captopril / Q000494:pharmacology; D002302:Cardiac Output / Q000187:drug effects*; D004195:Disease Models, Animal; D004285:Dogs; D004656:Enalapril; D005730:Ganglionic Blockers / Q000494:pharmacology; D006978:Hypertension, Renovascular / Q000188:drug therapy / Q000503:physiopathology*; D008297:Male; D010425:Pentolinium Tartrate / Q000494:pharmacology; D010656:Phenylephrine / Q000494:pharmacology; D014655:Vascular Resistance / Q000187:drug effects*; D014662:Vasoconstrictor Agents / Q000494:pharmacology*
D000806:Angiotensin-Converting Enzyme Inhibitors; D005730:Ganglionic Blockers; D014662:Vasoconstrictor Agents; D001127:Arginine Vasopressin; D010656:Phenylephrine; D004656:Enalapril; D010425:Pentolinium Tartrate; D002216:Captopril